Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
Top Cited Papers
Open Access
- 18 December 2024
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 36 (4) , 387-392
Abstract
No abstract availableKeywords
Funding Information
- Merck Healthcare KGaA
- Pfizer
- Merck
This publication has 8 references indexed in Scilit:
- Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trialESMO Open, 2024
- Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyJournal of Clinical Oncology, 2024
- Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 StudyEuropean Urology, 2023
- Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate useTrials, 2023
- Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaESMO Open, 2023
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaAnnals of Oncology, 2020
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2019
- Kidney CancerJournal of the National Comprehensive Cancer Network, 2009